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Abstract Well-standardized primary treatment and long-
term management of differentiated thyroid carcinoma
(DTC) include lowering or suppression of host thyrotro-
pin (TSH) with exogenous L-thyroxine (T4). This treat-
ment recognizes the trophic action of TSH on DTC
cells. Suppression of endogenous TSH with T4 is con-
tinued in recurrent disease. However, T4 can induce
proliferation of follicular and papillary thyroid carcino-
ma cell lines and of other human carcinoma cells. The
proliferative mechanism is initiated at a cell surface
receptor for T4 on integrin αvβ3, a receptor by which
the hormone also inhibits p53-dependent apoptosis in
tumor cells. In recurrent DTC with satisfactory suppres-
sion of endogenous TSH, we discuss here the possibility
that the tumor is no longer TSH dependent and that T4
has become a critical growth factor for the cancer.
Management of Differentiated Thyroid Carcinoma
Differentiated thyroid carcinoma (DTC) accounts for about
90 % of thyroid cancers [40]. Initial and long-term manage-
ment guidelines provided by the American Thyroid Associa-
tion have worked to standardize the surgical, radioablative,
and medical treatment of differentiated thyroid carcinoma
(DTC) [16] and have drawn a number of substantial com-
ments [63, 70, 73]. A key feature of DTC treatment is the
lowering in low risk or the suppression in higher risk DTC
patients of circulating endogenous pituitary thyrotropin
(TSH). Reduction of patient TSH release is achieved with
exogenous thyroid hormone (L-thyroxine, T4). TSH is a
growth factor for papillary and follicular thyroid cancer, and
successful TSH suppression therapy assumes a functional
TSH receptor (TSHR) in thyroid cells whose activity is min-
imized by the dearth of circulating TSH. The risks and bene-
fits of TSH suppression therapy have been reviewed in detail
by Biondi and Cooper [4].
Recurrence of disease occurs in 15 % or more of DTC
patients [52], with a higher incidence of recurrence in patients
over the age of 65 years [34]. Recurrence may be a product of
patient noncompliance with the TSH suppression regimen,
but, in the compliant patient, the molecular basis of recurrent
tumor is not clear. The tumor cell TSH receptor (TSHR) may
be a hyperfunctional mutant in DTC (2726) and thus may
respond over time in residual cancer cells to low-but-
detectable circulating levels of TSH. However, the frequency
of TSHRmutations in DTC is variable [9]. The state of p53 in
the remaining tumor cells may also determine lesion aggres-
siveness [57]. That a silenced TSHR is often present in the
case of undifferentiated thyroid cancers [28, 54] is certainly
consistent with the existence of endogenous growth or regu-
latory factors that are alternatives to TSH and may support
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thyroid tumor cell proliferation. There are a number of exam-
ples of such factors, including the epidermal growth factor
(EGF) axis [39, 82] and platelet-derived growth factor
(PDGF) [29, 83]. While it is important to growth of various
cancers, the EGF receptor in papillary DTC in terms of abun-
dance and affinity appears to be the same in tumoral and
adjacent normal thyroid tissue [53]. On the other hand, PDGF
may promote lymphatic metastases in DTC [83], and vascular
endothelial growth factor (VEGF) supports development of
lymph node metastases from DTC, at least in certain ethnic
populations [10]. Insulin-like growth factor 1 (IGF-1) is a
trophic factor for DTC [69]. Thyroid transcription factor 1
(TTF-1) may be localized to the nucleus in differentiated
thyroid carcinoma with increased frequency in the settings
of recurrent or persistent disease [27]. Hormonal regulation of
TTF-1 has not been well studied [5].
Certain genemutations occur in DTC but have had variable
success as predictors of recurrence. BRAF mutations, partic-
ularly V600E, have drawn particular attention in DTCs [1, 18,
26, 37, 66].
Given the above information, the possibility should be
considered that additional endogenous growth factors exist
for DTC in the absence of TSH that will support recurrence.
One such factor is thyroid hormone (see next section) which
has been shown to have proliferative effects on follicular and
papillary thyroid carcinoma cells [48].
Proliferative and Anti-apoptotic Actions of Thyroid
Hormone at Integrin αvβ3 on DTC and Other Tumor
Cells
Integrin αvβ3 is a structural protein of the plasma membrane
that binds specific extracellular matrix proteins and is critical
to cell-cell and cell-matrix interactions [64, 76]. It is amply
expressed by and activated in cancer cells and rapidly dividing
blood vessel cells [21]. The protein has been recently appre-
ciated to contain small molecular receptor sites for androgen
[45], resveratrol [43], and thyroid hormone [2, 21, 41]. Acting
at its receptor on αvβ3, thyroid hormone (L-thyroxine, T4;
3,5,3′-triiodo-L-thyronine, T3) has been shown to be pro-
angiogenic [12, 20, 51] and to induce proliferation in a variety
of human cancer cells. The latter includes glioblastoma [46],
lung [55], pancreas [81], and kidney [79] cells. The thyroid
hormone receptor on the integrin has no structural homologies
with the classical nuclear thyroid hormone receptor (TR) [14,
41]. Theαvβ3-based actions of the hormone are nongenomic,
in that they are independent of the T3-TR interactions that are
the basis of the genomic mechanism of hormone action. From
the integrin, however, T4 can modulate genomic actions of T3
[22] by affecting the trafficking of TR from cytoplasm to
nucleus [8], the state of phosphorylation of TR [23], and the
formation of TR-coactivator protein complexes [44]. The
presence ofαvβ3 has been confirmed in the many solid tumor
cell lines with which we have worked (HY Lin; unpublished
observations), regardless of putatively aggressive phenotype.
Studies by others in nonthyroid solid tumor cell lines have
indicated that αvβ3 confers recurrence behavior when other
factors, such as chemokine CCL2 [49] or matrix
metalloproteinase-9 (MMP-9) [33], are also present.
As noted above, we have shown that follicular thyroid
cancer cells and papillary thyroid carcinoma cells [48] prolif-
erate in vitro in response to T4 at physiologic free concentra-
tions. The proliferative response requires MAPK (ERK1/2)
activation and is blocked by RGD peptide, indicating the
effect is initiated at the hormone receptor site on αvβ3. These
observations raise the possibility that endogenous thyroid
hormone can be a growth factor for undiagnosed thyroid
cancer. That in patients with an established diagnosis of
DTC there may be recurrent local and metastatic thyroid
cancer despite successful suppression of endogenous TSH
release with pharmacologic thyroid hormone may have tro-
phic effects on the recurrent tumor. The proliferative effect of
T4 (10
−10 M free hormone) on thyroid cancer cells has been
observed in nonmutant cell lines, including TTF-1-expressing
cells, in Ret/PC1-positive cells [48], and in heterozygous
BRAF(V600E)/wt cells (HY Lin: unpublished observations).
A second approach which has been used to examine the
proliferative actions of thyroid hormone on DTC cells in vitro
involves tetraiodothyroacetic acid (tetrac), the naturally occur-
ring deaminated analog of T4. Tetrac inhibits the trophic
effects of T4 and T3 on a variety of tumor cells [46, 47, 55],
including papillary and follicular cancer cells [48]. This action
depends upon inhibition by tetrac of the binding of thyroid
hormone to integrin αvβ3 [20]. Tetrac formulations—includ-
ing nanoparticulate tetrac that is excluded from the cell inte-
rior—have been shown to arrest the growth of human follic-
ular thyroid carcinoma xenografts [78], xenografts of medul-
lary thyroid carcinoma [80], and other human solid tumor
xenografts [58, 79, 81]. Such observations are consistent with
actions of thyroid hormone as a trophic factor for can-
cers, including DTC. But, it should be noted that tetrac
has anti-cancer and anti-angiogenic effects that are ad-
ditive to its activity as an inhibitor of iodothyronine
binding to the integrin [21].
Thyroid hormone has a number of other actions that may
support solid tumor growth. The hormone is pro-angiogenic
[19, 51] by several mechanisms, including enhancement of the
angiogenic activities of VEGF, FGF2 (bFGF), and PDGF
[51]. Interestingly, the hormone may inhibit proliferative ac-
tion of IGF-1 in myoblasts [36] but amplifies IGF-1 signaling
in chondrocytes [74] and other cells [61]. This suggests that
thyroid hormone effects on this growth factor are complex and
may be tissue specific. The hormone stimulates miR-21 pro-
duction that enhances metastasis [35], as does hormonal ac-
tion to repress miR-17 [50]. The hormone causes transcription
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of a panel of metalloproteinase genes (MMP-2, MMP-3 [60],
and MMP-9 [15, 60, 65]) that support tumor dispersal/metas-
tasis. A number of these actions are initiated at integrin αvβ3.
Differential expression of genes in cancer cells that code for
regulatory proteins important to the cell cycle is also stimu-
lated by thyroid hormone [71]. Thyroid hormone has anti-
apoptotic actions in a variety of cells [11, 13, 25, 42, 47, 48,
62, 67, 72, 84]. We have shown that the hormone can block
pharmacologic induction of p53-dependent apoptosis [48] by
interfering with Ser-15 phosphorylation of p53. We would
point out that the hormone has also been reported to cause
apoptosis, but the models typically involve hyperthyroidism
in intact animals or very high doses of the hormone in vitro,
e.g., 250–500 μM [75, 77]. Finally, the pro-angiogenic activ-
ity of thyroid hormone [51] may be interpreted as a support
mechanism for cancers.
The affinity of the thyroid hormone receptor on plasma
membrane integrin αvβ3 is higher for T4 than T3 [2]. Func-
tionally, this means that supraphysiologic amounts of T3 are
required to induce proliferation in vitro, as shown, for exam-
ple, in human glioblastoma cells [46]. In contrast, concentra-
tions of free T4 of 10
−10 M or less are proliferative. This has
raised the possibility of lowering tumor patient circulating T4
levels via suppression of patient TSH with antithyroid drug
therapy [32] or exogenous T3 [30, 31]. This strategy is
discussed in the next section.
Is Recurrent DTC in Part an Expression of Actions
of Thyroid Hormone?
This question is not a denial of the role of TSH in support of
differentiated thyroid cancer or of the utility of the lowering of
TSH or its suppression in this clinical setting. We would agree
that in the large majority of DTC patients, the relative impor-
tance of TSH and the proliferative and/or anti-apoptotic activ-
ity of thyroid hormone used to suppress endogenous TSH
strongly favors the contribution of endogenous TSH and is a
requirement for its suppression.
On the other hand, the mechanisms for recurrence or re-
lapse of well-differentiated papillary or follicular thyroid can-
cer in the fully TSH-suppressed patient have not been satis-
factorily defined. That thyroid hormone, notably as T4, stim-
ulates tumor cell proliferation and is anti-apoptotic has been
repeatedly demonstrated [42, 47, 48] in a variety of cell lines
in vitro, including follicular and papillary thyroid cancer cells,
as noted above. The αvβ3 integrin that mediates such hor-
monal activity is amply expressed by cancer cells and by
endothelial cells involved in tumor-related angiogenesis. This
mechanism is independent of nuclear TR.
There are several strategies that may be discussed to test the
concept that T4 used to suppress endogenous TSH may con-
tribute adversely to tumor behavior in patients with recurrent
DTC. First, TSH-suppressive administration of T3 may be
substituted for L-thyroxine. T3 may be administered suffi-
ciently frequently to assure suppression of endogenous TSH
and achieve frank reduction in circulatingT4 levels. The clin-
ical endpoint is number and size of recurrent tumors. This
approach anecdotally has resulted in decreased size of certain
cancers [30, 31], but has not been tested against DTC.
Second, when recurrent DTC occurs in the setting of full
TSH suppression with T4, the treatment with T4 may be
interrupted for several months. The TSH may be allowed to
rise into the normal range or higher, and symptomatic hypo-
thyroidism would be managed with sufficient L-thyroxine to
abolish symptoms. The intent of reinstitution of T4 treatment
is not to return serum TSH to the normal range, but only to
relieve symptoms. The clinical endpoint again is number and
size of recurrent tumors. Without satisfactory documentation
that, in fact, T4 has replaced TSH as a growth factor for the
tumor, this approach cannot be used.
Third, thyroid hormone responsiveness of biopsied recur-
rent, invasive DTC might be tested in one or model systems.
One such approach involves xenografting of tumor biopsy
cells into the chick chorioallantoic membrane (CAM) system,
with biomarker response testing of the cells to TSH and,
separately, to T4. The results may then direct subsequent
management. This is a personalized medicine approach that
we have elsewhere suggested may be used in the future to
define pharmacodynamics of multiple chemotherapeutic
agents against recurrent cancers of various types [24]. Tumor
cell radiosensitivity can also be evaluated in the CAM.
A final point for discussion is that deaminated thyroid
hormone analogs are agents that suppress pituitary TSH se-
cretion. Tetrac [7] and triac [6, 7, 38] have been shown to be
effective inhibitors of TSH secretion and have been consid-
ered for use in the setting of thyroid cancer. As discussed
above, tetrac also blocks the proliferative actions of T4 on
tumor cells that are initiated atαvβ3 [21, 41] and triac also has
been shown to inhibit nongenomic actions of T4 [19]. The use
of either of these agents may suppress host TSH and, inde-
pendently of this action, inhibit DTC tumor cell proliferation.
The approach has an important disadvantage. Unmodified
tetrac and triac are taken up by nonmalignant cells and are
thyromimetic in such cells [56], albeit low grade. Such
thyromimetic effects in noncancer cells may have interrupted
the proposed commercial development of unmodified tetrac as
a TSH-suppressing drug. In contrast, nanoparticulate tetrac—
a compound in which the tetrac is covalently bound to a
biodegradable nanoparticle [3, 21]—is not internalized by
any cells and expresses its anti-tumor and anti-angiogenic
activity exclusively atαvβ3 in the plasmamembrane. Limited
to the cell exterior, however, nanoparticulate tetrac is not a
suppressor of pituitary TSH secretion.
A section of the guidelines of the American Thyroid As-
sociation for management of DTC includes an essay on
HORM CANC (2015) 6:7–12 9
directions for future research [16]. Emphases are placed on
disruption of oncogenic signaling pathways, particularly
MAPK, on modulation of proliferation and apoptosis and on
development or use of inhibitors of angiogenesis. These
themes appear to us to be very relevant to the possibility we
raise here that TSH-suppressive doses of T4 in the patient
population with recurrent, aggressive DTC may then contrib-
ute to the clinical growth of the tumor. The proliferative
actions of T4 initiated at αvβ3 are MAPK dependent [46];
T4 is anti-apoptotic [42, 47, 48] and T4 is pro-angiogenic [20,
51]. Thus, consideration of the elimination of these actions of
T4 in cancer cells that express αvβ3 has some attractiveness.
Studies to determine whether T4 is a proliferative factor in
xenografts have not yet been carried out, but induced or
spontaneous hypothyroidism in patients with glioblastoma
[32], renal cell carcinoma [68], nonthyroidal head and neck
cancers [59], and breast carcinoma [17] has favorably affected
tumor behavior.
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